Latest Articles

Publication Date
Endometriosis as a Silent Emerging Malignant Threat in Young Women: A Case Report of Rare Rapid Transformation of Abdominal Wall Endometriosis Into Mixed High-Grade Serous and Clear Cell Carcinoma One Year Following Cesarean Section.

Abdominal wall endometriosis most commonly occurs in cesarean section (CS) scars. Although malignant transformation is rare, clear cell carcinoma (CCC) is the most commonly reported histological subtype. We present an …

Published: Aug. 6, 2026, midnight
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - Clinical Oncology News

Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer Clinical Oncology News

Published: Aug. 3, 2026, 3:32 p.m.
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - clinicaloncology.com

Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer clinicaloncology.com

Published: Aug. 3, 2026, 3:31 p.m.
Impact of the Etiology of Diminished Ovarian Reserve on Assisted Reproductive Technology Outcomes: A Multicenter Retrospective Cohort Study.

To investigate whether the etiology of diminished ovarian reserve (DOR) independently influences outcomes of assisted reproductive technology (ART).

Published: July 31, 2026, midnight
Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial - Yahoo Finance

Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial Yahoo Finance

Published: July 27, 2026, 10:08 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Sahm

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Sahm

Published: July 16, 2026, 10:27 a.m.
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk

Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk

Published: July 15, 2026, 11:49 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Benzinga

Published: July 15, 2026, 5:25 p.m.
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer - OncLive

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer OncLive

Published: July 15, 2026, 3:58 p.m.
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!